The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...

A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...

Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness, ...

RSV is the most common cause of hospitalization in infants under 1 year old. The infection can spread to the lungs and cause ...

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

AstraZeneca and Sanofi now have the data they need in hand to press ahead with regulatory filings next year for nirsevimab, an antibody designed to prevent respiratory syncytial virus (RSV ...

IDWeek 2024 was held at the Los Angeles Convention Center in Downtown Los Angeles, CA, USA, from 16–19 October. Phoebe Hall ...

It is the first approval for Beyfortus (nirsevimab) by any regulatory authority. AZ's Synagis (palivizumab) is currently the only approved drug in Europe to provide passive prophylaxis against RSV ...

Seasonal maternal respiratory syncytial virus vaccination and nirsevimab for infants demonstrate cost-effectiveness. HealthDay News — Seasonal maternal respiratory syncytial virus (RSV) vaccination ...

In a second study, Hutton and colleagues simulated health care utilization and deaths from RSV with and without nirsevimab among infants aged 0 to 7 months and aged 8 to 19 months during a single RSV ...

Russia has fired at least 60 North Korean-supplied ballistic missiles against Ukraine during the war, Radio Free Europe/Radio Liberty reports. Ukrainian military spokesperson Andrii Chernyak told ...